Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772935 | 0.98 | STAT3 (0.57) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL23772833 | 0.98 | STAT3 (0.57) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL23772804 | 0.98 | STAT3 (0.57) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL25756441 | 0.92 | STAT3 (0.57) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL13643751 | 0.91 | CRBN (0.59) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL16582168 | 0.90 | MAP1LC3B (0.59) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL29612686 | 0.89 | STAT3 (0.68) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL22580836 | 0.89 | CRBN (0.58) | CRBNDDB1BRD4MAP1LC3B | |
| SCHEMBL21106602 | 0.89 | STAT3 (0.68) | CRBNDDB1STAT3BRD4MAP1LC3B | |
| SCHEMBL23037309 | 0.89 | STAT3 (0.57) | CRBNDDB1STAT3BRD4MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | Aurigene Oncology Technologies Limited (IN) | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885DDB1 683/4885STAT3 3371/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 384/4885DDB1 665/4885STAT3 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.